Results 81 to 90 of about 22,264 (222)
Complement and cytokine response in acute Thrombotic Thrombocytopenic Purpura [PDF]
Complement dysregulation is key in the pathogenesis of atypical Haemolytic Uraemic Syndrome (aHUS), but no clear role for complement has been identified in Thrombotic Thrombocytopenic Purpura (TTP).
Heelas, E +4 more
core +1 more source
Fulminant myocarditis in immune‐mediated thrombotic thrombocytopenic purpura: A case report
Background Thrombotic thrombocytopenic purpura is a life‐threatening thrombotic microangiopathy characterized by systemic microvascular thrombosis. Cardiovascular complications, including myocardial ischemia and necrosis, are a leading cause of acute ...
Haruka Ishikita +5 more
doaj +1 more source
ABSTRACT In 2007, the American Society for Apheresis (ASFA) published guidance for physician documentation related to oversight of therapeutic apheresis (TA). Due to 21st century changes in healthcare delivery, the ASFA Board of Directors (BOD) charged its Public Affairs and Advocacy Committee (PAAC) to coordinate a review and update of the guidance ...
Chester Andrzejewski +8 more
wiley +1 more source
Eculizumab for Gemcitabine-Induced Hemolytic Uremic Syndrome: A Novel Therapy for an Emerging Condition [PDF]
Introduction Atypical hemolytic uremic syndrome (aHUS), a thrombotic microangiopathy (TMA), is a disease characterized by hemolytic anemia, thrombocytopenia, and renal impairment. Gemcitabine, a commonly used chemotherapy, is emerging as a cause of aHUS.
Karkowsky, MD, Raphael +1 more
core +2 more sources
Introduction. Sunitinib malate is an oral multitargeting tyrosine kinase inhibitor approved for the first line treatment of metastatic renal cell carcinoma.
Imane El Dika +4 more
doaj +1 more source
Successful Treatment of Aplastic Anemia With Eltrombopag During Pregnancy: A Short Report
ABSTRACT Introduction Aplastic anemia (AA) is a rare bone marrow failure syndrome with pancytopenia, mainly due to immune‐mediated stem cell destruction. First‐line therapy for acquired severe AA ≥ 50 years/non‐severe AA (NSAA) requiring treatment is immunosuppressive therapy with horse anti‐thymocyte globulin, cyclosporine A (CSA), and eltrombopag ...
Sandra M. Frey +3 more
wiley +1 more source
ADAMTS-13 and Von Willebrand factor in relation to platelet response during plasma exchange in thrombotic thrombocytopenic purpura: a clue for disease mechanism? [PDF]
International ...
M. C. Kappers-Klunne +2 more
core +2 more sources
Introduction Since the first description of Thrombotic Thrombocytopenic Purpura, caused by a severe deficiency of ADAMTS13, plasma exchange and immunosuppression have become standard treatments, allowing to decrease its high mortality rate.
Daniel Cathalifaud +6 more
doaj +1 more source
Hump-nosed viper bites are frequent in southern India and Sri Lanka. However, the published literature on this snakebite is limited and its venom composition is not well characterized.
Milinda Withana +3 more
doaj +1 more source
Tuberculosis presenting as immune thrombocytopenic purpura [PDF]
Background Although various hematologic abnormalities are seen in tuberculosis, immune thrombocytopenic purpura is a rare event. Case Presentation We report a case of a 29 year-old male who was presented with immune thrombocytopenia-induced hemoptysis ...
Bahadir-Erdogan Beril +7 more
core +2 more sources

